Clinical trial · Observational
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Arterial Infusion Chemotherapy | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Lenvatinib | — | UNRESOLVED | — |
| PD-1 Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Hepatic arterial infusion chemotherapy | Procedure | — | UNRESOLVED |
| Lenvatinib | Drug | Lenvatinib | ALIAS |
| Sintilimab | Drug | Sintilimab | ALIAS |
| Tislelizumab | Drug | Tislelizumab | ALIAS |
| Toripalimab | Drug | Toripalimab | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- HAIC+Len+PD-1 inhibitor group
- description
- HAIC combined with Lenatinib and PD-1 inhibitor group
- interventionNames
- Procedure: Hepatic arterial infusion chemotherapy
- Drug: Lenvatinib
- Drug: Tislelizumab
- Drug: Toripalimab
- Drug: Sintilimab
- Drug: Camrelizumab
- label
- Len group
- description
- Lenvatinib alone
- interventionNames
- Drug: Lenvatinib
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. primary infiltrative HCC according to MRI or CT imaging characteristics. 2. Child-Pugh class A or B, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 3. Lenvatinib as initial treatment. 4. patients received HAIC and PD-1 inhibitor in HAIC+Len+PD-1 group, patients received Lenvatinib alone in Len group. 5. no history of other malignancies. 6. no tumor thrombus in the atrium or vena cava. Exclusion Criteria: 1. HCC with tumor capsule. 2. under 18 years or over 75 years. 3. TACE as initial treatment. 4. sorafenib or other systemic therapy with or without PD-1 inhibitor following HAIC. 5. incomplete tumor imaging data. 6. lost to follow-up after treatment within three months.
References
Publications (0)
Data not yet available